Eisai Inc. develops and markets pharmaceuticals to treat a variety of ills. As the US production arm of Eisai Co., its roster includes Alzheimer's treatment Aricept, Aciphex for acid reflux, anti-seizure medication Banzel, anticoagulant Fragmin, lymphoma drug Ontak, and anti-convulsant Zonegran. In addition to neurology, oncology, and vascular ailments, the firm has drug research, development, marketing, and manufacturing programs in areas including infectious disease, inflammation, and critical care. The company supplies its products to health care professionals, pharmacies, and hospitals through wholesale distributors.
Eisai Inc. also employs a direct sales force of about 900 representatives located in New Jersey; the reps promote its products to doctors and other health care customers. The firm's research and development operations span discovery and process research, clinical research, and the formulation and manufacturing of drugs used in clinical research from locations in Pennsylvania and Massachusetts.
The company also operates a commercial drug manufacturing plant in North Carolina that focuses on making solid oral dose medications. In 2010 the facility was expanded to add capacity for the manufacturing of paraenteral (intravenous) medications. Eisai Inc. also has a small specialty drug plant in Maryland.
Following the loss of US patent protection for top selling drug Aricept in 2010, Eisai Inc. has been focused on growth efforts, including R&D and acquisitions. In addition to launching new formulations of the Aricept product, Eisai Inc. introduced a new breast cancer drug, Halaven, into the US market in 2010. Additional development efforts focus on neurology, vascular ailments, inflammation, and infectious disease treatments.
As parent company Eisai Co. has aggressively acquired new US businesses in recent years, the new divisions have been rolled into the Eisai Inc. organization. One such unit, Morphotek (acquired in 2007), conducts research on cancer, inflammation, and infection treatments. Eisai Inc.'s line of commercial and development-stage oncology products was greatly expanded with the buy of MGI PHARMA for some $3.9 billion in 2008.
In early 2010 Eisai acquired US-based biotech firm AkaRx, a developer of thrombocytopenia, a blood disorder affecting liver disease and cancer chemotherapy patients, for $255 million. Eisai Inc. had previously gained AkaRx as a development partner through its acquisition of MGI.
Subsidiaries Eisai Research Institute of Boston and Eisai Medical Research, previously held under the Eisai Corporation of North America division of parent Eisai Co. (and serving as the company's R&D arm), were merged into Eisai Inc. in 2009.
Another subsidiary, Eisai Machinery USA, is responsible for marketing and sales of the Japanese parent's pharmaceutical inspection equipment to US-based customers. The division operates from a separate location in New Jersey. – less